Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.20.1
Commitments and Contingencies (Details Textual)
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2020
USD ($)
Feb. 28, 2020
CNY (¥)
Feb. 24, 2020
USD ($)
Feb. 24, 2020
CNY (¥)
Aug. 29, 2019
USD ($)
Oct. 23, 2018
USD ($)
May 29, 2018
Oct. 25, 2017
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
Oct. 23, 2018
CNY (¥)
Commitments and Contingencies (Textual)                        
Joint venture agreement, description           Within 6 days of signing the AVAR Agreement, Avactis is required to pay to Arbele $300,000 as a research and development fee with an additional two payments of $300,000 (for a total of $900,000) to be paid upon mutually agreed upon milestones.            
Research and development fee                 $ 275,402 $ 152,460    
Line of Credit Agreement [Member]                        
Commitments and Contingencies (Textual)                        
Line of credit         $ 20,000,000              
Line of facility mature date         Dec. 31, 2024              
Line of Credit bears interest at an annual rate         5.00%              
Recevied Loan                 2,900,000      
Avalon Shanghai [Member]                        
Commitments and Contingencies (Textual)                        
Joint venture agreement, description             Avalon Shanghai entered into a Joint Venture Agreement with Jiangsu Unicorn Biological Technology Co., Ltd. ("Unicorn"), pursuant to which a company named Epicon Biotech Co., Ltd. ("Epicon") was formed on August 14, 2018. Epicon is owned 60% by Unicorn and 40% by Avalon Shanghai. Within two years of execution of the Joint Venture Agreement, Unicorn shall invest cash into Epicon in an amount not less than RMB 8,000,000 (approximately $1.1 million) and the premises of the laboratories of Nanjing Hospital of Chinese Medicine for exclusive use by Epicon, and Avalon Shanghai shall invest cash into Epicon in an amount not less than RMB 10,000,000 (approximately $1.4 million). Epicon is focused on cell preparation, third party testing, biological sample repository for commercial and scientific research purposes and the clinical transformation of scientific achievements. As of March 31, 2020, Avalon Shanghai has contributed RMB 4,100,000 (approximately $0.6 million) that was included in equity method investment on the accompanying consolidated balance sheets.          
AVAR BioTherapeutics (China) Co. Ltd. [Member]                        
Commitments and Contingencies (Textual)                        
Joint venture agreement, description           Avactis Biosciences, Inc. ("Avactis"), a wholly-owned subsidiary of the Company, and Arbele Limited ("Arbele") agreed to the establishment of AVAR BioTherapeutics (China) Co. Ltd. ("AVAR"), a Sino-foreign equity joint venture, pursuant to an Equity Joint Venture Agreement (the "AVAR Agreement"), which will be owned 60% by Avactis and 40% by Arbele. The purpose and business scope of the Joint Venture is to research, develop, produce, sell, distribute and generally commercialize CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy in China. Avactis is required to contribute $10 million (or equivalent in RMB) in cash and/or services, which shall be contributed in tranches based on milestones to be determined jointly by AVAR and Avactis in writing subject to Avactis' cash reserves. Within 30 days, Arbele shall make a contribution of $6.66 million in the form of entering into a License Agreement with AVAR granting AVAR with an exclusive right and license in China to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology and any additional technology developed in the future with terms and conditions to be mutually agreed upon Avactis and AVAR and services.            
Working capital           $ 700,000            
Research and development fee                 800,000      
RMB [Member] | AVAR BioTherapeutics (China) Co. Ltd. [Member]                        
Commitments and Contingencies (Textual)                        
Working capital | ¥                       ¥ 5,000,000
Beijing Genexosome Office Lease [Member]                        
Commitments and Contingencies (Textual)                        
Expiration period Apr. 14, 2021 Apr. 14, 2021                    
Lease, total rent $ 1,400                      
Lease, monthly rent 120                      
Rent expense                 55      
Future minimum rental payment                 1,358      
Security deposit $ 700                      
Lease, description The term of the lease is 13 months commencing on March 15, 2020 and expires on April 14, 2021 with one month of free rent. The term of the lease is 13 months commencing on March 15, 2020 and expires on April 14, 2021 with one month of free rent.                    
Operating lease                 85,301      
Stock purchase agreement, description               Beijing Genexosome and Yu Zhou, MD, PhD, the sole shareholder of Beijing Genexosome, pursuant to which Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome in consideration of a cash payment in the amount of $450,000, of which $100,000 is still owed. Further, on October 25, 2017, Genexosome entered into and closed an Asset Purchase Agreement with Dr. Zhou, pursuant to which the Company acquired all assets, including all intellectual property and exosome separation systems, held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies. In consideration of the assets, Genexosome paid Dr. Zhou $876,087 in cash, transferred 500,000 shares of common stock of the Company to Dr. Zhou and issued Dr. Zhou 400 shares of common stock of Genexosome.        
Beijing Genexosome Office Lease [Member] | RMB [Member]                        
Commitments and Contingencies (Textual)                        
Lease, total rent $ 10,000                      
Lease, monthly rent $ 833                      
Security deposit | ¥   ¥ 5,000                    
Avalon Shanghai Office Lease [Member]                        
Commitments and Contingencies (Textual)                        
Expiration period     Feb. 28, 2021 Feb. 28, 2021                
Lease, monthly rent     $ 7,000                  
Rent expense                 8,000      
Security deposit     23,000                  
Operating lease maintenance fees     $ 600                  
Lease, description     The term of the Beijing Office Lease is 12 months commencing on March 1, 2020 and expires on February 28, 2021. The term of the Beijing Office Lease is 12 months commencing on March 1, 2020 and expires on February 28, 2021.                
Avalon Shanghai Office Lease [Member] | RMB [Member]                        
Commitments and Contingencies (Textual)                        
Lease, monthly rent | ¥       ¥ 50,586                
Security deposit | ¥       164,764                
Operating lease maintenance fees | ¥       ¥ 4,336                
New York Lease [Member]                        
Commitments and Contingencies (Textual)                        
Expiration period                     Dec. 31, 2022  
Lease, monthly rent                     $ 6,000  
Rent expense                 $ 18,000      
Lease, description                     The term of the New York Lease is 3 years commencing on January 1, 2020 and expires on December 31, 2022.